Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.

Authors

Christoph Wanner
John M Lachin, George Washington UniversityFollow
Silvio E Inzucchi
David Fitchett
Michaela Mattheus
Jyothis T George
Hans-Juergen Woerle
Uli C Broedl
Maximilian von Eynatten
Bernard Zinman

Document Type

Journal Article

Publication Date

9-13-2017

Journal

Circulation

DOI

10.1161/CIRCULATIONAHA.117.028268

APA Citation

Wanner, C., Lachin, J., Inzucchi, S., Fitchett, D., Mattheus, M., George, J., Woerle, H., Broedl, U., von Eynatten, M., & Zinman, B. (2017). Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.. Circulation, (). http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028268

Peer Reviewed

1